Serine protease inhibition prevents both cellular and humoral responses to cardiopulmonary bypass

Journal of Cardiovascular Pharmacology

Volumn 27, Issue SUPPL. 1, 1996, Pages

  Royston, David ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Aprotinin; Cardiopulmonary bypass; Coagulation; Inflammation; Polymorphonuclear leukocyte; Serine protease inhibitors

Indexed keywords

APROTININ; GABEXATE MESILATE; NAFAMSTAT; NAFAMSTAT MESILATE; SERINE PROTEINASE INHIBITOR; THROMBIN;

ARTICLE; CARDIOPULMONARY BYPASS; DRUG MECHANISM; DRUG THERAPY; FIBRIN CLOT; FIBRINOLYSIS; HOST RESISTANCE; HUMAN; INFLAMMATION; NEUTROPHIL; PRIORITY JOURNAL; PROTEINASE INHIBITION; THROMBOGENICITY; TISSUE INJURY;

EID: 0030053106     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199600001-00010     Document Type: Article

References (60)

1. Iwanaga S, Muta T, Shigenaga T, et al. Role of hemocyte-derived granular components in invertebrate defense. Ann NY Acad Sci 1994;712:102-16.
2. Muta T, Oda T, Iwanaga S. Horseshoe crab coagulation factor B. A unique serine protease zymogen activated by cleavage of an Ile-Ile bond. J Biol Chem 1993;268:21384-8.
3. Muta T, Tokunaga F, Nakamura T, Monta T, Iwanage S. Limulus clotting factor C: lipopolysaccharide-sensitive serine protease zymogen. Methods Enzymol 1993;223:336-45.
4. Miura Y, Kawabata S, Iwanaga S. A Limulus intracellular coagulation inhibitor with characteristics of the SERPIN superfamily. Purification, characterization, and cDNA cloning. J Biol Chem 1994;269:542-7.
5. Tapparelli C, Metternich R, Ehrhardt C, Cook NS. Synthetic low-molecular-weight thrombin inhibitors: molecular design and pharmacological profile. Trends Pharmacol Sci 1993; 14: 366-76.
6. Blajchman MA. An overview of the mechanism of action of antithrombin and its inherited deficiency states. Blood Coag Fibrinolys 1994;5(suppl 1):S5-11; discussion S59-64.
7. Jeske W, Fareed J. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues. Semin Thromb Hemost 1993; 1: 241-7.
8. Bregengaard C, Nordfang O, Ostergaard P, et al. Pharmacokinetics of full-length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemost 1993;70:454-7.
9. Bregengaard C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coag Fibrinolys 1993;4:699-706.
10. Hamamoto T, Yamamoto M, Nordfang O, Petersen JG, Foster DC, Kisiel W. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces. J Biol Chem 1993;268:8704-10.
11. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittel-forschung 1983;33:479-94.
12. Laskowski M, Kato I. Protein inhibitors of proteinases. Annu Rev Biochem 1980;49:593-626.
13. Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 1985; 15:164-8.
14. Koshiyama Y, Ozeki M, Motoyoshi A, Fujita M, Iwaki M, Aoyama T. Pharmacological studies of FUT-175, nafamstat mesilate. IV. Effects on coagulation, platelets and fibrinolysis. Nippon Yakurigaku Zasshi 1984;84:417-28.
15. Nishijima J, Hiraoka N, Murata A, et al. Protease inhibitors (gabexate mesilate and ulinastatin) stimulate intracellular chemiluminescence in human neutrophils. J Leukocyte Biol 1992;52:262-8.
16. Ohno H, Kosaki G, Kambayashi J, Imaoka S, Hirata F. FOY: [ethyl P-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. I. Inhibition of thrombin and factor Xa in vitro. Thromb Res 1980;19:579-88.
17. Redl H, Schlag G, Paul E, Schiesser A. Cellular (thrombocytes, granulocytes) effects of proteinase inhibitors - gabexylate, gabexate mesilate (FOY) and aprotinin. Resuscitation 1986; 14: 81-90.
18. Royston D. The serine antiprotease aprotinin (Trasylol): a novel approach to reducing postoperative bleeding. Blood Coag Fibrinolys 1990; 1:55-69.
19. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth 1992;6:76-100.
20. Tanaka K, Kondo C, Takagi K, et al. Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery. ASAIO J 1993; 39:M545-9.
21. Taenaka N, Shimada Y, Hirata T, Nishijima M, Yoshiya I. New approach to regional anticoagulation in hemodialysis using gabexate mesilate (FOY). Crit Care Med 1982; 10:773-5.
22. Fareed J, Hoppensteadt D, Walenga JM, Bick RL. Current trends in the development of anticoagulant and antithrombotic drugs. Med Clin North Am 1994;78:713-31.
23. Griffin LC, Toole JJ, Leung LL. The discovery and characterization of a novel nucleotide-based thrombin inhibitor. Gene 1993;137:25-31.
24. Johnson PH. Hirudin: clinical potential of a thrombin inhibitor. Annu Rev Med 1994;45:165-77.
25. Katakura S, Nagahara T, Hara T, Iwamoto M. A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin. Biochem Biophys Res Commun 1993;197:965-72.
26. Komatsu Y, Misawa S, Sukesada A, Ohba Y, Hayashi H. CX-397, a novel recombinant hirudin analog having a hybrid sequence of hirudin variants-1 and -3. Biochem Biophys Res Commun 1993;196:773-9.
27. Li WX, Kaplan AV, Grant GW, Toole JJ, Leung LL. A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. Blood 1994;83:677-82.
28. Lidon RM, Theroux P, Lesperance J, et al. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994;89:1567-72.
29. Mesters RM, Heeb MJ, Griffin JH. A novel exosite in the light chain of human activated protein C essential for interaction with blood coagulation factor Va. Biochemistry 1993;32: 12656-63.
30. Nagahara T, Yokoyama Y, Inamura K, et al. Dibasic (amidinoaryl) propanoic acid derivatives as novel blood coagulation factor Xa inhibitors. J Med Chem 1994;37:1200-7.
31. Neises B, Tarnus C, Broersma RJ, Bald C, Remy JM, Heminger EF. The synthesis and anticoagulant activity of novel peptidylfluoroalkanes. Adv Exp Med Biol 1993;340:185-8.
32. Nishino T, Nishioka C, Ura H, Nagumo T. Isolation and partial characterization of a novel amino sugar-containing fucan sulfate from commercial Fucus vesiculosus fucoidan. Carbohydr Res 1994;255:213-24.
33. Oleksyszyn J, Boduszek B, Kam CM, Powers JC. Novel amidine-containing peptidyl phosphonates as irreversible inhibitors for blood coagulation and related serine proteases. J Med Chem 1994;37:226-31.
34. Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost 1993;70: 212-6.
35. Murase M, Usui A, Tomita Y, Maeda M, Koyama T, Abe T. Nafamostat mesilate reduces blood loss during open heart surgery. Circulation 1993;88:432-6.
36. Whitten C, Latson T, Allison P, et al. Does aprotinin inhibit cardiopulmonary bypass-induced inflammation? [Abstract]. Anesthesiology 1992;77:A266.
37. Hunyadi J, Kenderessy AS, Duda E, Braquet P, Dobozy A. Platelet-activating factor antagonists (BN 52021 and BN 50730) inhibit tumor necrosis factor-a-mediated cytotoxicity on murine L929 tumor cells. Mol Immunol 1993;30:517-9.
38. Bazil V, Strominger JL. Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. Induction of cleavage of L-selectin via CD16. J Immunol 1994;152:1314-22.
39. van Oeveren W, Jansen NJ, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987;44:640-5.
40. Dietrich W, Mossinger H, Spannagl M, et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations [Comment]. J Thorac Cardiovasc Surg 1993;105:712-20.
41. Marx G, Pokar H, Reuter H, Doering V, Tilsner V. The effects of aprotinin on hemostatic function during cardiac surgery. J Cardiothorac Vasc Anesth 1991;5:467-74.
42. Lord RA, Roath OS, Thompson JF, Chant AD, Francis JL. Effect of aprotinin on neutrophil function after major vascular surgery. Br J Surg 1992;79:517-21.
43. Hallett MB, Shandall A, Young HL. Mechanism of protection against "reperfusion injury" by aprotinin. Roles of polymorphonuclear leucocytes and oxygen radicals. Biochem Pharmacol 1985;34:1757-61.
44. 2) and hydroxyl radical production by human polymorphonuclear leukocytes. Hepatogastroenterology 1992;39:59-61.
45. Royston D, Fleming J, Desai J, Westaby S, Taylor KMT. Increased peroxide product generation associated with open heart surgery: evidence for free-radical generation. J Thorac Cardiovasc Surg 1986;91:759-66.
46. Royston D, Bidstrup B, Fleming J, Taylor K. Platelet preservation reduces production of lipid peroxidation products during cardiopulmonary bypass in humans [Abstract]. Am Rev Respir Dis 1987;135:A135.
47. Liu B, Belboul A, Al-Khaja N, et al. Effect of high-dose aprotinin on blood cell filterability in association with cardiopulmonary bypass. Coronary Artery Dis 1992;3:129-32.
48. Cumming AD, Nimmo GR, Craig KJ, McGilchrist A, Hayes PC. Vasoactive effects of aprotinin. Agents Actions 1992; 38(suppl):211-8.
49. Williams G, Pickup JC, Bowcock S, Cooke E, Keen H. Subcutaneous aprotinin causes local hyperaemia. A possible mechanism by which aprotinin improves control in some diabetic patients. Diabetologia 1983;24:91-4.
50. Homeister JW, Satoh P, Lucchesi BR. Effects of complement activation in the isolated heart. Role of the terminal complement components. Circ Res 1992;71:303-19.
51. Welbourn R, Goldman G, O'Riordain M, et al. Role for tumor necrosis factor as mediator of lung injury following lower torso ischemia. J Appl Physiol 1991;70:2645-9.
52. Welbourn CR, Goldman G, Paterson IS, Valeri CR, Shepro D, Hechtman HB. Neutrophil elastase and oxygen radicals: synergism in lung injury after hind-limb ischemia. Am J Physiol 1991;260:H1852-6.
53. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Aprotinin in cardiopulmonary bypass - effects on the Hageman factor (FXII)-kallikrein system and blood loss. Blood Coag Fibrinolys 1992;3:99-104.
54. Heller W, Fuhrer G, Gallimore MJ, Michel J, Hoffmeister HE. Changes in the kallikrein-kinin-system after different dose regimen of aprotinin during cardiopulmonary bypass operation. Adv Exp Med Biol 1989;247b:43-8.
55. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981;304:497-503.
56. Faymonville ME, Pincemail J, Duchateau J, et al. Myeloperoxidase and elastase as markers of leukocyte activation during cardiopulmonary bypass in humans [Comment]. J Thorac Cardiovasc Surg 1991;102:309-17.
57. Mair P, Mair J, Seibt I, Furtwaengler W, Balogh D, Puschendorf B. Plasma elastase concentrations and pulmonary function after cardiopulmonary bypass [Letter]. J Thorac Cardiovasc Surg 1994;108:184-5.
58. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;106:1008-16.
59. Haeffner-Cavaillon N, Roussellier N, Ponzio O, et al. Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1989;98:1100-6.
60. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994;108:626-35.